Clinical trials: Adjuvant Treatment
Carcinoma, Non-Small-Cell Lung, Next-Generation Sequencing
Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC
This clinical trial aims to explore the minimal residual disease (MRD) status of early NSCLC after curative surgery and the clinical outcomes of adjuvant chemotherapy.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Next-Generation Sequencing, Chemotherapy, Adjuvant, Neoplasm, Residual
- Trial name
- NCT05167604
- Testing
- Adjuvants, Pharmaceutic
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Tang-Du Hospital
Carpal Tunnel Syndrome, PRP
PRP as Adjuvant Treatment to CTR for Severe CTS Tunnel Syndrome
This study assesses the potential benefit of adjuvant platelet-rich plasma (PRP) with carpal tunnel release (CTR) for patients with severe carpal tunnel syndrome (CTS).
- Trial name
- NCT04811287
- Testing
- Carpal Tunnel Release with Platelet-Rich Plasma, Carpal Tunnel Release without Platelet-Rich Plasma
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Michael Fredericson, MD
Glioma, Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4)
A Study of 177Lu-PSMA-617 in People With Gliomas
The researchers are doing this study to find out whether the radiopharmaceutical therapy (RPT) 177Lu-PSMA-617 is a safe treatment for people with IDH wild type glioma.
- Conditions
- Glioma, Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4), Glioblastoma, IDH-wildtype, Diffuse Midline Glioma, H3 K27-Altered
- Trial name
- NCT07223034
- Testing
- Temozolomide, 177Lu-PSMA-617, 68Ga-PSMA-PET scan/ MRI
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Brain Tumors, Central Nervous System Tumors
Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma
RATIONALE: Radiation therapy uses high energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00002875
- Testing
- filgrastim, cisplatin, cyclophosphamide
- Where
- 41 sites in United States, Australia and 3 more
- Volunteers
- 421 people
- Sponsor
- Children's Oncology Group
Geriatric Assessment, Adjuvant Drug Therapy
Aspects of Adjuvant CDK4/6 Inhibitors in Older Breast Cancer Patients - Focusing on Geriatric Screening
Older breast cancer patients should not be categorically excluded from adjuvant therapies, including the recommended CDK4/6 inhibitors (CDK4/6i) administered in combination with endocrine therapy.
- Conditions
- Geriatric Assessment, Adjuvant Drug Therapy, Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Trial name
- FUTURE (NCT07273357)
- Where
- 5 sites in Sweden
- Volunteers
- 200 people
- Sponsor
- Region Jönköping County
Prostate Cancer
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
VA Cooperative Study #553 is designed to prospectively evaluate the efficacy of early adjuvant chemotherapy using docetaxel and prednisone added to the standard of care for patients who are potentially cured by radical…
- Trial name
- CAP (NCT00132301)
- Testing
- Docetaxel, Prednisone
- Where
- 34 sites in United States, Puerto Rico
- Volunteers
- 298 people
- Sponsor
- VA Office of Research and Development
Esophageal Squamous Cell Carcinoma
Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC
Esophageal cancer, the 7th most common cancer globally, accounts for more than half a million deaths each year. The incidence of ESCC, the most common histologic type, has been stable, whereas the incidences of esophageal and…
- Trial name
- NCT05213312
- Testing
- Nivolumab, Cisplatin, Paclitaxel
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Shanghai Zhongshan Hospital
Breast Neoplasms
Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial
This is an open-label, multicenter, 2x2 factorial design, randomized controlled, Phase III study comparing the disease free survival after randomisation in patients treated with 3 cycles of…
- Trial name
- NCT02181101
- Testing
- FEC-DocGemzar adjuvant chemotherapy, FEC-Doc adjuvant chemotherapy, Zoledronic acid i.v. 2 years
- Where
- Germany
- Volunteers
- 3,754 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Breast Cancer
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
The scope of this study is to measure the impact of MammaPrint on treatment in Hormone Receptor (HR)-positive HER2-negative breast cancer patients.
- Trial name
- IMPACt (NCT02670577)
- Where
- 17 sites in United States
- Volunteers
- 481 people
- Sponsor
- Agendia
Post-COVID-19 Syndrome, Long COVID
Magnesium and Vitamin D Combination for Post-COVID Syndrome
The goal of this double-blind randomized controlled clinical trial is to determine the efficacy of the administration of magnesium chloride + vitamin D as an adjuvant in the treatment of post-Coronavirus Disease (COVID) syndrome.
- Conditions
- Post-COVID-19 Syndrome, Long COVID, Vitamin D Deficiency, Magnesium Deficiency
- Trial name
- NCT05630339
- Testing
- Magnesium chloride, Vitamin D
- Where
- Mexico
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Coordinación de Investigación en Salud, Mexico
Breast Cancer
Different Durations of Adjuvant Anastrozole Therapy After 2 to 3 Years Tamoxifen Therapy in Breast Cancer
The purpose of this study is to determine whether 6 years adjuvant anastrozole will improve the disease free survival compared to 3 years adjuvant anastrozole in postmenopausal hormone sensitive breast cancer patients, subsequent…
- Trial name
- DATA (NCT00301457)
- Testing
- Anastrozole
- Where
- 67 sites in Netherlands
- Volunteers
- 1,914 people
- Sponsor
- Maastricht University Medical Center
Beta Thalassemia
Evaluating the Effect of N-Acetyl Cysteine and Alpha Lipoic Acid in Patients With Beta Thalassemia
The current study is to investigate the potential roles of N-acetyl cysteine and Alpha-lipoic acid in patients with beta-thalassemia.
- Trial name
- NAC/ALA (NCT07157722)
- Testing
- Iron chelating intervention, N Acetyl cysteine 600mg, Alpha Lipoic Acid 600 MG Oral Tablets
- Where
- Egypt
- Volunteers
- 66 people
- Sponsor
- Tanta University
Colorectal Cancer, Chemotherapy Effect
Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients
The goal of this clinical trial] is to compare in resectable stage T3-4N2 colorectal cancer. The main question it aims to answer is: whether the use of targeted therapy in combination with adjuvant chemotherapy is associated with…
- Trial name
- NCT05797467
- Testing
- FOLFOX chemotherapy regimens, Bevacizumab
- Where
- China
- Volunteers
- 366 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Rectal Cancer
Adjuvant Chemotherapy After Preoperative Chemoradiotherapy to Treat Rectal Cancer
The purpose of this study is to evaluate the disease-free survival in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy with fluoropyrimidines and surgery followed by adjuvant combination…
- Trial name
- NCT00807911
- Testing
- Adjuvant FL, Adjuvant FOLFOX
- Where
- 6 sites in South Korea
- Volunteers
- 322 people
- Sponsor
- Asan Medical Center
Breast Cancer
Weekly Docetaxel and CMF in the Adjuvant Treatment of Elderly Women With High-Risk Breast Cancer
This trial will evaluate the effectiveness of standard adjuvant treatment with CMF chemotherapy versus treatment with weekly docetaxel in patients with high-risk breast cancer who are 65 years of age and older or are poor…
- Trial name
- NCT00193011
- Testing
- Docetaxel, Cyclophosphamide, Methotrexate
- Volunteers
- 150 people
- Sponsor
- SCRI Development Innovations, LLC
LA HNSCC
A Prospective, Exploratory Study of Becotatug Vedotin Plus Putlimab for Neoadjuvant Therapy and Adjuvant Radiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
This is a prospective, exploratory, non-registration, multi-center clinical study to evaluate the efficacy and safety of becotatug vedotin (EGFR-ADC) combined with putlimab and radiotherapy in the perioperative treatment of…
- Trial name
- NCT07707167
- Testing
- Pucotenlimab, Becotatug vedotin, Radiotherapy
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Endometrial Neoplasms
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
The purpose of this study is to compare pembrolizumab + adjuvant chemotherapy with placebo + adjuvant chemotherapy, with or without radiotherapy, with respect to disease-free survival (DFS) as assessed radiographically by the…
- Trial name
- NCT04634877
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- 231 sites in United States, Argentina and 26 more
- Volunteers
- 990 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer
Physical Activity Intervention on Myocardial Function in Patients With HER2 + Breast Cancer
Purpose of the study is to examine the effects of 3 months of physical activity intervention on myocardial function (Left ventricular ejection fraction) in patients with HER2+ breast cancer
- Trial name
- CARDAPAC (NCT02433067)
- Testing
- Physical activity intervention, Control Group
- Where
- France
- Volunteers
- 89 people
- Sponsor
- University of Franche-Comté
Breast Cancer
PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer
This is a single center, prospective cross-sectional study of women who have completed therapy for primary breast cancer within 5 years of diagnosis and are at increased risk for relapse.
- Trial name
- NCT02732171
- Testing
- Research Blood Collection
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Malignant Melanoma Stage II
Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma
Stage II patients with primary surgical treatment of cuMM are often at risk for recurrence of their disease. This risk may be reduced by adjuvant systemic treatment.
- Trial name
- NivoMela (NCT04309409)
- Testing
- Nivolumab
- Where
- 20 sites in Germany
- Volunteers
- 374 people
- Sponsor
- University Hospital, Essen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.